

Cervical Cancer Screening Policy 2016 References

- ¹ On April 1, 2015 Merck's new HPV vaccine, Gardasil 9, was approved for use in Canada. Gardasil 9 targets HPV types 16, 18, 9, 11, 31, 33, 45, 52 and 58.
- ² Ronco G, Dillner J, Elfström KM et al. Efficacy of HPV-based screening for prevention of invasive cervical cancer: follow-up of four European randomised controlled trials. *The Lancet*. 2014; 383(9916): 524-32.
- ³ BC Cervical Cancer Screening Program, *2013 Annual Report*. Available online at <http://www.screeningbc.ca/NR/rdonlyres/21BBF070-6504-4A37-A1BB-45563BF387C7/70872/CCSPAnnualReport2013VersionJuly2014Web1.pdf>. Accessed June, 2015.
- ⁴ It should be noted that any reference to HPV testing in this document is specifically referring to high-risk HPV infection, as detected by current tests. HPV types classified as 'high-risk' include 16, 18, 31, 33, 35, 39, 45, 51, 52, 56, 58, 59, 66 and 68.
- ⁵ Brinton LA, Tashima KT, Lehman HF et al. Epidemiology of cervical cancer by cell type. *Cancer Research*. 1987; 47(6): 1706-11.
- ⁶ Copeland G, Datta SD, Spivak G et al. Total burden and incidence of in situ and invasive cervical carcinoma in Michigan, 1985-2003. *Cancer*. 2008; 113(10 Suppl): 2946-54.
- ⁷ Mathew A and George PS. Trends in incidence and mortality rates of squamous cell carcinoma and adenocarcinoma of cervix--worldwide. *Asian Pacific Journal of Cancer Prevention*. 2009; 10(4): 645-50.
- ⁸ Liu S, Semenciw R, Probert A et al. Cervical cancer in Canada: changing patterns in incidence and mortality. *International Journal of Gynecological Cancer*. 2001; 11(1): 24-31.
- ⁹ Smith HO, Tiffany MF, Qualls CR et al. The rising incidence of adenocarcinoma relative to squamous cell carcinoma of the uterine cervix in the United States--a 24-year population-based study. *Gynecologic Oncology*. 2000; 78(2): 97-105.
- ¹⁰ Liu S, Semenciw R, Probert A et al. Cervical cancer in Canada: changing patterns in incidence and mortality. *International Journal of Gynecological Cancer*. 2001; 11(1): 24-31.
- ¹¹ Coldman A, Phillips N, Kan L et al. Risk of invasive cervical cancer after three consecutive negative Pap smears. *Journal of Medical Screening*. 2003; 10(4): 196-200.
- ¹² Andersson S, Larson B, Hjerpe A et al. Adenocarcinoma of the uterine cervix: the presence of human papillomavirus and the method of detection. *Acta Obstetrica et Gynecologica Scandinavica*. 2003; 82(10): 960-5.
- ¹³ International Collaboration of Epidemiological Studies in Cervical Cancer. Comparison of risk factors for invasive squamous cell carcinoma and adenocarcinoma of the cervix: collaborative reanalysis of individual data on 8,097 women with squamous cell carcinoma and 1,374 women with adenocarcinoma from 12 epidemiological studies. *International Journal of Cancer*. 2007; 120(4): 885-91.
- ¹⁴ Sasieni P, Castanon A and Cuzick J. Screening and adenocarcinoma of the cervix. *International Journal of Cancer*. 2009; 125(3): 525-9.
- ¹⁵ Bulk S, Van Kemenade FJ, Rozendaal L et al. The Dutch CISOE-A framework for cytology reporting increases efficacy of screening upon standardisation since 1996. *Journal of Clinical Pathology*. 2004; 57(4): 388-93.
- ¹⁶ Schnatz PF, Guile M, O'Sullivan DM et al. Clinical significance of atypical glandular cells on cervical cytology. *Obstetrics and Gynecology*. 2006; 107(3): 701-8.
- ¹⁷ Zhao C, Florea A, Onisko A et al. Histologic follow-up results in 662 patients with Pap test findings of atypical glandular cells: results from a large academic womens hospital laboratory employing sensitive screening methods. *Gynecologic Oncology*. 2009; 114(3): 383-9.
- ¹⁸ Castle PE, Fetterman B, Poitras N et al. Relationship of atypical glandular cell cytology, age, and human papillomavirus detection to cervical and endometrial cancer risks. *Obstetrics and Gynecology*. 2010; 115(2 Pt 1): 243-8.

- ¹⁹ Srodon M, Parry Dilworth H and Ronnett BM. Atypical squamous cells, cannot exclude high-grade squamous intraepithelial lesion: diagnostic performance, human papillomavirus testing, and follow-up results. *Cancer*. 2006; 108(1): 32-8.
- ²⁰ Sherman ME, Castle PE and Solomon D. Cervical cytology of atypical squamous cells-cannot exclude high-grade squamous intraepithelial lesion (ASC-H): characteristics and histologic outcomes. *Cancer*. 2006; 108(5): 298-305.
- ²¹ Davey DD, Greenspan DL, Kurtycz DF et al. Atypical squamous cells, cannot exclude high-grade squamous intraepithelial lesion: review of ancillary testing modalities and implications for follow-up. *Journal of Lower Genital Tract Disease*. 2010; 14(3): 206-14.
- ²² Krueger H, Stuart G, Gallagher R, Williams D, Kerner J. *HPV and Other Infectious Agents in Cancer: Opportunities for Prevention and Public Health*. New York: Oxford University Press; 2010.
- ²³ Walboomers JM, Jacobs MV, Manos MM et al. Human papillomavirus is a necessary cause of invasive cervical cancer worldwide. *The Journal of Pathology*. 1999; 189(1): 12-9.
- ²⁴ Arbyn M, Tommasino M, Depuydt C et al. Are 20 human papillomavirus types causing cervical cancer? *Journal of Pathology*. 2014; 234(4): 431-5.
- ²⁵ de Sanjose S, Diaz M, Castellsague X et al. Worldwide prevalence and genotype distribution of cervical human papillomavirus DNA in women with normal cytology: a meta-analysis. *The Lancet Infectious Diseases*. 2007; 7(7): 453-9.
- ²⁶ Leinonen M, Nieminen P, Kotaniemi-Talonen L et al. Age-specific evaluation of primary human papillomavirus screening vs conventional cytology in a randomized setting. *Journal of the National Cancer Institute*. 2009; 101(23): 1612-23.
- ²⁷ Ogilvie G, Cook D, Taylor D et al. Population-based evaluation of type-specific HPV prevalence among women in British Columbia, Canada. *Vaccine*. 2013; 31(7): 1129-33.
- ²⁸ Jayasinghe YL, Moore EE, Tabrizi SN et al. Human papillomavirus in adolescents: lessons learned from decades of evaluation. *Journal of Paediatrics and Child Health*. 2013; 49(2): 99-104.
- ²⁹ Vaccarella S, Franceschi S, Herrero R et al. Sexual behavior, condom use, and human papillomavirus: pooled analysis of the IARC human papillomavirus prevalence surveys. *Cancer Epidemiology, Biomarkers & Prevention*. 2006; 15(2): 326-33.
- ³⁰ International Collaboration of Epidemiological Studies in Cervical Cancer. Cervical carcinoma and sexual behavior: collaborative reanalysis of individual data on 15,461 women with cervical carcinoma and 29,164 women without cervical carcinoma from 21 epidemiological studies. *Cancer Epidemiology, Biomarkers & Prevention*. 2009; 18(4): 1060-9.
- ³¹ Moscicki AB, Shiboski S, Broering J et al. The natural history of human papillomavirus infection as measured by repeated DNA testing in adolescent and young women. *The Journal of Pediatrics*. 1998; 132(2): 277-84.
- ³² Woodman CB, Collins S, Winter H et al. Natural history of cervical human papillomavirus infection in young women: a longitudinal cohort study. *The Lancet*. 2001; 357(9271): 1831-6.
- ³³ Moscicki AB. Management of adolescents who have abnormal cytology and histology. *Obstetrics and Gynecology Clinics of North America*. 2008; 35(4): 633-43; x.
- ³⁴ Ho GY, Bierman R, Beardsley L et al. Natural history of cervicovaginal papillomavirus infection in young women. *The New England Journal of Medicine*. 1998; 338(7): 423-8.
- ³⁵ Jayasinghe YL, Moore EE, Tabrizi SN et al. Human papillomavirus in adolescents: lessons learned from decades of evaluation. *Journal of Paediatrics and Child Health*. 2013; 49(2): 99-104.
- ³⁶ Rodriguez AC, Schiffman M, Herrero R et al. Rapid clearance of human papillomavirus and implications for clinical focus on persistent infections. *Journal of the National Cancer Institute*. 2008; 100(7): 513-7.
- ³⁷ Castle PE, Schiffman M, Herrero R et al. A prospective study of age trends in cervical human papillomavirus acquisition and persistence in Guanacaste, Costa Rica. *The Journal of Infectious Diseases*. 2005; 191(11): 1808-16.

- ³⁸ Kjaer SK, van den Brule AJ, Paull G et al. Type specific persistence of high risk human papillomavirus (HPV) as indicator of high grade cervical squamous intraepithelial lesions in young women: population based prospective follow up study. *BMJ*. 2002; 325(7364): 572.
- ³⁹ Kjaer SK, Frederiksen K, Munk C et al. Long-term absolute risk of cervical intraepithelial neoplasia grade 3 or worse following human papillomavirus infection: role of persistence. *Journal of the National Cancer Institute*. 2010; 102(19): 1478-88.
- ⁴⁰ Krueger H, Stuart G, Gallagher R, Williams D, Kerner J. *HPV and Other Infectious Agents in Cancer: Opportunities for Prevention and Public Health*. New York: Oxford University Press; 2010.
- ⁴¹ Melnikow J, Nuovo J, Willan AR et al. Natural history of cervical squamous intraepithelial lesions: a meta-analysis. *Obstetrics and Gynecology*. 1998; 92(4 Pt 2): 727-35.
- ⁴² Moscicki A-B, Shiboski S, Hills NK et al. Regression of low-grade squamous intra-epithelial lesions in young women. *The Lancet*. 2004; 364(9446): 1678-83.
- ⁴³ Winer RL, Kiviat NB, Hughes JP et al. Development and duration of human papillomavirus lesions, after initial infection. *The Journal of Infectious Diseases*. 2005; 191(5): 731-8.
- ⁴⁴ Moore K, Cofer A, Elliot L et al. Adolescent cervical dysplasia: histologic evaluation, treatment, and outcomes. *American Journal of Obstetrics and Gynecology*. 2007; 197(2): 141 e1-6.
- ⁴⁵ Moscicki AB, Ma Y, Wibbelsman C et al. Rate of and risks for regression of cervical intraepithelial neoplasia 2 in adolescents and young women. *Obstetrics and Gynecology*. 2010; 116(6): 1373-80.
- ⁴⁶ van Oortmarsen GJ and Habbema JD. Epidemiological evidence for age-dependent regression of pre-invasive cervical cancer. *British Journal of Cancer*. 1991; 64(3): 559-65.
- ⁴⁷ Gravitt PE. The known unknowns of HPV natural history. *The Journal of Clinical Investigation*. 2011; 121(12): 4593-9.
- ⁴⁸ Markt SC, Rodriguez AC, Burk RD et al. Longitudinal analysis of carcinogenic human papillomavirus infection and associated cytologic abnormalities in the Guanacaste natural history study: looking ahead to cotesting. *The Journal of Infectious Diseases*. 2012; 205(3): 498-505.
- ⁴⁹ International Agency for Research on Cancer. Cervical cancer and screening. In: eds. *IARC Handbook of Cancer Prevention: Volume 10: Cervical Cancer Screening*. Lyon: IARC Press; 2005.
- ⁵⁰ Holowaty P, Miller AB, Rohan T et al. Natural history of dysplasia of the uterine cervix. *Journal of the National Cancer Institute*. 1999; 91(3): 252-8.
- ⁵¹ Ostor AG. Natural history of cervical intraepithelial neoplasia: a critical review. *International Journal of Gynecological Pathology*. 1993; 12(2): 186-92.
- ⁵² Alternate terminology includes Pap or Papanicolaou smear, cervical smear, cervical/vaginal cytology.
- ⁵³ Michalas SP. The Pap test: George N. Papanicolaou (1883-1962). A screening test for the prevention of cancer of uterine cervix. *European Journal of Obstetrics and Gynecology and Reproductive Biology*. 2000; 90(2): 135-8.
- ⁵⁴ Sankaranarayanan R, Nene BM, Shastri SS et al. HPV screening for cervical cancer in rural India. *New England Journal of Medicine*. 2009; 360(14): 1385-94.
- ⁵⁵ Grossman J and Mackenzie FJ. The randomized controlled trial: gold standard, or merely standard? *Perspectives in Biology and Medicine*. 2005; 48(4): 516-34.
- ⁵⁶ See, for example, the flaws in RCTs of breast cancer screening identified by Gotzsche PC, Nielsen M. Screening for breast cancer with mammography. *Cochrane Database of Systematic Reviews*. 2009.
- ⁵⁷ International Agency for Research on Cancer. Effectiveness of screening in populations. In: eds. *IARC Handbook of Cancer Prevention: Volume 10: Cervical Cancer Screening*. Lyon: IARC Press; 2005.
- ⁵⁸ Anderson GH, Boyes DA, Benedet JL et al. Organisation and results of the cervical cytology screening programme in British Columbia, 1955-85. *British Medical Journal*. 1988; 296(6627): 975-8.

- ⁵⁹ Adapted from Wilson J and Jungner G. *Principles and Practice of Screening for Disease*. 1968. World Health Organization. Available at http://whqlibdoc.who.int/php/WHO_PHP_34.pdf. Accessed January 2012. & Public Health Agency of Canada. *Performance Monitoring for Cervical Cancer Screening Programs in Canada*. 2009. Available at <http://www.phac-aspc.gc.ca/cd-mc/cancer/pmccspc-srpdcuc/pdf/cervical-eng.pdf>. Accessed January 2012.
- ⁶⁰ Miller D. *Gynaecologic Oncology Program in British Columbia: Right Care, Right Time, Right Place*. 2007 Available at http://www.icccassociation.com/2007/speaker_presentations/pdf/DianneMiller.pdf. Accessed January 2012.
- ⁶⁰ About half of the Canadian provinces and territories receive this designation, with the balance being characterized as having “spontaneous” approaches—the more familiar term for this would be “opportunistic.” Only Saskatchewan’s program is deemed to be “organized.” Public Health Agency of Canada. *Performance Monitoring for Cervical Cancer Screening Programs in Canada*. 2009. Available at <http://www.phac-aspc.gc.ca/cd-mc/cancer/pmccspc-srpdcuc/pdf/cervical-eng.pdf>. Accessed January 2012.
- ⁶² Canadian Task Force on Preventive Health Care. Recommendations on screening for cervical cancer. *Canadian Medical Association Journal*. 2013; 185(1): 35-45.
- ⁶³ Gibb RK and Martens MG. The impact of liquid-based cytology in decreasing the incidence of cervical cancer. *Reviews in Obstetrics and Gynecology*. 2011; 4(Suppl 1): S2-S11.
- ⁶⁴ Naucler P, Ryd W, Tornberg S et al. Efficacy of HPV DNA testing with cytology triage and/or repeat HPV DNA testing in primary cervical cancer screening. *Journal of the National Cancer Institute*. 2009; 101(2): 88-99.
- ⁶⁵ Nanda K, McCrory DC, Myers ER et al. Accuracy of the Papanicolaou test in screening for and follow-up of cervical cytologic abnormalities: a systematic review. *Annals of Internal Medicine*. 2000; 132(10): 810-9.
- ⁶⁶ Coldman A, Phillips N, Kan L et al. Risk of invasive cervical cancer after three consecutive negative Pap smears. *Journal of Medical Screening*. 2003; 10(4): 196-200.
- ⁶⁷ Morrison BJ, Coldman AJ, Boyes DA et al. Forty years of repeated screening: the significance of carcinoma in situ. *British Journal of Cancer*. 1996; 74(5): 814-9.
- ⁶⁸ Coldman A, Phillips N, Kan L et al. Risk of invasive cervical cancer after Pap smears: the protective effect of multiple negatives. *Journal of Medical Screening*. 2005; 12(1): 7-11.
- ⁶⁹ Castle PE, Fetterman B, Poitras N et al. Five-year experience of human papillomavirus DNA and Papanicolaou test cotesting. *Obstetrics and Gynecology*. 2009; 113(3): 595-600.
- ⁷⁰ Dickinson JA, Stankiewicz A, Popadiuk C et al. Reduced cervical cancer incidence and mortality in Canada: national data from 1932 to 2006. *BioMed Central Public Health*. 2012; 12(1): 992.
- ⁷¹ Läärä E, Day N and Hakama M. Trends in mortality from cervical cancer in the Nordic countries: association with organised screening programmes. *The Lancet*. 1987; 329(8544): 1247-9.
- ⁷² Quinn M, Babb P, Jones J et al. Effect of screening on incidence of and mortality from cancer of cervix in England: evaluation based on routinely collected statistics. *British Medical Journal*. 1999; 318(7188): 904-8.
- ⁷³ International Agency for Research on Cancer. Effectiveness of screening in populations. In: eds. *IARC Handbook of Cancer Prevention: Volume 10: Cervical Cancer Screening*. Lyon: IARC Press; 2005.
- ⁷⁴ Anderson GH, Boyes DA, Benedet JL et al. Organisation and results of the cervical cytology screening programme in British Columbia, 1955-85. *British Medical Journal*. 1988; 296(6627): 975-8.
- ⁷⁵ Ibid.
- ⁷⁶ Sasieni PD, Cuzick J and Lynch-Farmery E. Estimating the efficacy of screening by auditing smear histories of women with and without cervical cancer. The National Co-ordinating Network for Cervical Screening Working Group. *British Journal of Cancer*. 1996; 73(8): 1001-5.

- ⁷⁷ Cuzick J, Clavel C, Petry KU et al. Overview of the European and North American studies on HPV testing in primary cervical cancer screening. *International Journal of Cancer*. 2006; 119(5): 1095-101.
- ⁷⁸ Reelick NF, de Haes WF and Schuurman JH. Psychological side-effects of the mass screening on cervical cancer. *Social Science & Medicine*. 1984; 18(12): 1089-93.
- ⁷⁹ Bell S, Porter M, Kitchener H et al. Psychological response to cervical screening. *Preventive Medicine*. 1995; 24(6): 610-6.
- ⁸⁰ Gray NM, Sharp L, Cotton SC et al. Psychological effects of a low-grade abnormal cervical smear test result: anxiety and associated factors. *British Journal of Cancer*. 2006; 94(9): 1253-62.
- ⁸¹ Korfage IJ, van Ballegooijen M, Huveneers H et al. Anxiety and borderline PAP smear results. *European Journal of Cancer*. 2010; 46(1): 134-41.
- ⁸² Heinonen A, Tapper A-M, Leminen A et al. Health-related quality of life and perception of anxiety in women with abnormal cervical cytology referred for colposcopy: an observational study. *European Journal of Obstetrics & Gynecology and Reproductive Biology*. 2013; 169(2): 387-91.
- ⁸³ Sharp L, Cotton S, Carsin AE et al. Factors associated with psychological distress following colposcopy among women with low-grade abnormal cervical cytology: a prospective study within the Trial Of Management of Borderline and Other Low-grade Abnormal smears (TOMBOLA). *Psycho-Oncology*. 2013; 22(2): 368-80.
- ⁸⁴ Bell S, Porter M, Kitchener H et al. Psychological Response to Cervical Screening. *Preventive medicine*. 1995; 24(6): 610-6.
- ⁸⁵ Korfage IJ, van Ballegooijen M, Huveneers H et al. Anxiety and borderline PAP smear results. *European Journal of Cancer*. 2010; 46(1): 134-41.
- ⁸⁶ Hellsten C, Sjöström K and Lindqvist P. A longitudinal 2-year follow-up of quality of life in women referred for colposcopy after an abnormal cervical smear. *European Journal of Obstetrics & Gynecology and Reproductive Biology*. 2009; 147(2): 221-5.
- ⁸⁷ Korfage IJ, Essink-Bot M-L, Westenberg SM et al. How distressing is referral to colposcopy in cervical cancer screening?: a prospective quality of life study. *Gynecologic Oncology*. 2014; 132(1): 142-8.
- ⁸⁸ Bell S, Porter H, Kitchener H et al. Psychological response to cervical cancer screening *Preventive Medicine*. 1995; 24(6): 610-16.
- ⁸⁹ Gray NM, Sharp L, Cotton SC et al. Psychological effects of a low-grade abnormal cervical smear test result: anxiety and associated factors. *British Journal of Cancer*. 2006; 94(9): 1253-62.
- ⁹⁰ Korfage IJ, van Ballegooijen M, Huveneers H et al. Anxiety and borderline PAP smear results. *European Journal of Cancer*. 2010; 46(1): 134-41.
- ⁹¹ Champion MJ, Brown JR, McCance DJ et al. Psychosexual trauma of an abnormal cervical smear. *British Journal of Obstetrics and Gynaecology*. 1988; 95(2): 175-81.
- ⁹² Hellsten C, Lindqvist P and Sjöström K. A longitudinal study of sexual functioning in women referred for colposcopy: a 2-year follow up. *BJOG: An International Journal of Obstetrics & Gynaecology*. 2008; 115(2): 205-11.
- ⁹³ French DP, Maissi E and Marteau TM. Psychological costs of inadequate cervical smear test results. *British journal of Cancer*. 2004; 91(11): 1887-92.
- ⁹⁴ Wilkinson C, Jones JM and McBride J. Anxiety caused by abnormal result of cervical smear test: a controlled trial. *British Medical Journal*. 1990; 300(6722): 440.
- ⁹⁵ Gibb RK and Martens MG. The impact of liquid-based cytology in decreasing the incidence of cervical cancer. *Reviews in Obstetrics and Gynecology*. 2011; 4(Suppl 1): S2-S11.
- ⁹⁶ Denny L. Cytological screening for cervical cancer prevention. *Best Practice & Research. Clinical Obstetrics & Gynaecology*. 2012; 26(2): 189-96.
- ⁹⁷ Ibid.
- ⁹⁸ Arbyn M, Bergeron C, Klinkhamer P et al. Liquid compared with conventional cervical cytology: a systematic review and meta-analysis. *Obstetrics and Gynecology*. 2008; 111(1): 167-77.

⁹⁹ For example, Siebers AG, Klinkhamer PJ, Grefte JM et al. Comparison of liquid-based cytology with conventional cytology for detection of cervical cancer precursors: a randomized controlled trial. *Journal of the American Medical Association*. 2009; 302(16): 1757-64.

¹⁰⁰ Whitlock EP, Vesco KK, Eder M et al. Liquid-based cytology and human papillomavirus testing to screen for cervical cancer: a systematic review for the U.S. Preventive Services Task Force. *Annals of Internal Medicine*. 2011; 155(10): 687-97, W214-5.

¹⁰¹ Sawaya GF. Evidence-based medicine versus liquid-based cytology. *Obstetrics and Gynecology*. 2008; 111(1): 2-3.

¹⁰² Nanda K, McCrory DC, Myers ER et al. Accuracy of the Papanicolaou test in screening for and follow-up of cervical cytologic abnormalities: a systematic review. *Annals of Internal Medicine*. 2000; 132(10): 810-9.

¹⁰³ Arbyn M, Bergeron C, Klinkhamer P et al. Liquid compared with conventional cervical cytology: a systematic review and meta-analysis. *Obstetrics and Gynecology*. 2008; 111(1): 167-77.

¹⁰⁴ Davey E, Barratt A, Irwig L et al. Effect of study design and quality on unsatisfactory rates, cytology classifications, and accuracy in liquid-based versus conventional cervical cytology: a systematic review. *The Lancet*. 2006; 367(9505): 122-32.

¹⁰⁵ Whitlock EP, Vesco KK, Eder M et al. Liquid-based cytology and human papillomavirus testing to screen for cervical cancer: a systematic review for the U.S. Preventive Services Task Force. *Annals of Internal Medicine*. 2011; 155(10): 687-97, W214-5.

¹⁰⁶ Schiffman M, Castle PE, Jeronimo J et al. Human papillomavirus and cervical cancer. *The Lancet*. 2007; 370(9590): 890-907.

¹⁰⁷ Cuzick J, Clavel C, Petry KU et al. Overview of the European and North American studies on HPV testing in primary cervical cancer screening. *International Journal of Cancer*. 2006; 119(5): 1095-101.

¹⁰⁸ Schiffman M, Wentzensen N, Wacholder S et al. Human papillomavirus testing in the prevention of cervical cancer. *Journal of the National Cancer Institute*. 2011; 103(5): 368-83.

¹⁰⁹ Whitlock EP, Vesco KK, Eder M et al. Liquid-based cytology and human papillomavirus testing to screen for cervical cancer: a systematic review for the U.S. Preventive Services Task Force. *Annals of Internal Medicine*. 2011; 155(10): 687-97, W214-5.

¹¹⁰ See

<http://www.fda.gov/medicaldevices/productsandmedicalprocedures/deviceapprovalsandclearances/recently-approveddevices/ucm082556.htm>. Accessed January, 2012.

¹¹¹ Arney A and Bennett K. Molecular diagnostics of human papillomavirus. *Laboratory Medicine*. 2010; 41(9): 523-30.

¹¹² U.S. Food and Drug Administration. *Recently Approved Devices: cobas® HPV Test - P100020/S008*. 2014. Available at

<http://www.fda.gov/MedicalDevices/ProductsandMedicalProcedures/DeviceApprovalsandClearances/Recently-ApprovedDevices/ucm395694.htm>. Accessed June 2015.

¹¹³ Roche Canada. *Media Release: Health Canada Approves Roche's HPV Test for First-Line Primary Screening of Cervical Cancer and Roche Launches New Cytology Test to Provide the Most Comprehensive Portfolio for Cervical Cancer Screening*. 2014. Available at

http://www.rochecanada.com/en/content/news/health_canada_approves_roches_hpv_test.html. Accessed June 2015.

¹¹⁴ Ratnam S, Coutlee F, Fontaine D et al. Aptima HPV E6/E7 mRNA test is as sensitive as Hybrid Capture 2 assay but more specific at detecting cervical precancer and cancer. *Journal of Clinical Microbiology*. 2011; 49(2): 557-64.

¹¹⁵ Hologic. *Aptima HPV Assay*. Available at <http://www.hologic.com/products/clinical-diagnostics-blood-screening/assays-and-tests/aptima-hpv-assay>. Accessed June 2015.

- ¹¹⁶ Tjalma WA and Depuydt CE. Don't forget HPV-45 in cervical cancer screening. *American Journal of Clinical Pathology*. 2012; 137(1): 161-2.
- ¹¹⁷ Cuzick J, Clavel C, Petry KU et al. Overview of the European and North American studies on HPV testing in primary cervical cancer screening. *International Journal of Cancer*. 2006; 119(5): 1095-101.
- ¹¹⁸ Koliopoulos G, Arbyn M, Martin-Hirsch P et al. Diagnostic accuracy of human papillomavirus testing in primary cervical screening: a systematic review and meta-analysis of non-randomized studies. *Gynecologic Oncology*. 2007; 104(1): 232-46.
- ¹¹⁹ Meijer CJ, Berkhof J, Castle PE et al. Guidelines for human papillomavirus DNA test requirements for primary cervical cancer screening in women 30 years and older. *International Journal of Cancer*. 2009; 124(3): 516-20.
- ¹²⁰ Kinney W, Stoler MH and Castle PE. Special commentary: patient safety and the next generation of HPV DNA tests. *American Journal of Clinical Pathology*. 2010; 134(2): 193-9.
- ¹²¹ Kurian EM, Caporelli ML, Baker S et al. Cervista HR and HPV 16/18 assays vs hybrid capture 2 assay: outcome comparison in women with negative cervical cytology. *American Journal of Clinical Pathology*. 2011; 136(5): 808-16.
- ¹²² Belinson JL, Wu R, Belinson SE et al. A population-based clinical trial comparing endocervical high-risk HPV testing using hybrid capture 2 and Cervista from the SHENCCAST II Study. *American Journal of Clinical Pathology*. 2011; 135(5): 790-5.
- ¹²³ Kurian EM, Caporelli ML, Baker S et al. Cervista HR and HPV 16/18 assays vs hybrid capture 2 assay: outcome comparison in women with negative cervical cytology. *American Journal of Clinical Pathology*. 2011; 136(5): 808-16.
- ¹²⁴ Belinson JL, Wu R, Belinson SE et al. A population-based clinical trial comparing endocervical high-risk HPV testing using hybrid capture 2 and Cervista from the SHENCCAST II Study. *American Journal of Clinical Pathology*. 2011; 135(5): 790-5.
- ¹²⁵ Wentzensen N, Gravitt PE, Solomon D et al. A study of Amplicor human papillomavirus DNA detection in the atypical squamous cells of undetermined significance-low-grade squamous intraepithelial lesion triage study. *Cancer Epidemiology, Biomarkers & Prevention*. 2009; 18(5): 1341-9.
- ¹²⁶ De Francesco MA, Gargiulo F, Schreiber C et al. Comparison of the AMPLICOR human papillomavirus test and the hybrid capture 2 assay for detection of high-risk human papillomavirus in women with abnormal PAP smear. *Journal of Virological Methods*. 2008; 147(1): 10-7.
- ¹²⁷ Dufresne S, Sauthier P, Mayrand MH et al. Human papillomavirus (HPV) DNA triage of women with atypical squamous cells of undetermined significance with Amplicor HPV and Hybrid Capture 2 assays for detection of high-grade lesions of the uterine cervix. *Journal of Clinical Microbiology*. 2011; 49(1): 48-53.
- ¹²⁸ Twigg LB and Hopkins M. High-risk HPV DNA testing and HPV-16/18 genotyping: what is the clinical application? *Journal of Lower Genital Tract Disease*. 2011; 15(3): 224-30.
- ¹²⁹ Heideman DA, Hesselink AT, Berkhof J et al. Clinical validation of the cobas 4800 HPV test for cervical screening purposes. *Journal of Clinical Microbiology*. 2011; 49(11): 3983-5.
- ¹³⁰ Arbyn M, Roelens J, Cuschieri K et al. The APTIMA HPV assay versus the hybrid capture 2 test in triage of women with ASC-US or LSIL cervical cytology: a meta-analysis of the diagnostic accuracy. *International Journal of Cancer*. 2013; 132(1): 101-8.
- ¹³¹ Dijkstra M, Snijders P, Arbyn M et al. Cervical cancer screening: on the way to a shift from cytology to full molecular screening. *Annals of Oncology*. 2014; 25: 927-35.
- ¹³² Castle PE, Cox JT, Jeronimo J et al. An analysis of high-risk human papillomavirus DNA-negative cervical precancers in the ASCUS-LSIL Triage Study (ALTS). *Obstetrics and Gynecology*. 2008; 111(4): 847-56.

- ¹³³ Kitchener HC, Gilham C, Sargent A et al. A comparison of HPV DNA testing and liquid based cytology over three rounds of primary cervical screening: extended follow up in the ARTISTIC trial. *European Journal of Cancer*. 2011; 47(6): 864-71.
- ¹³⁴ Katki HA, Kinney WK, Fetterman B et al. Cervical cancer risk for women undergoing concurrent testing for human papillomavirus and cervical cytology: a population-based study in routine clinical practice. *The Lancet Oncology*. 2011; 12(7): 663-72.
- ¹³⁵ McCaffery K, Waller J, Forrest S et al. Testing positive for human papillomavirus in routine cervical screening: examination of psychosocial impact. *British Journal of Obstetrics and Gynaecology*. 2004; 111(12): 1437-43.
- ¹³⁶ Maggino T, Casadei D, Panontin E et al. Impact of an HPV diagnosis on the quality of life in young women. *Gynecologic Oncology*. 2007; 107(1 Suppl 1): S175-9.
- ¹³⁷ Waller J, McCaffery K, Kitchener H et al. Women's experiences of repeated HPV testing in the context of cervical cancer screening: a qualitative study. *Psycho-oncology*. 2007; 16(3): 196-204.
- ¹³⁸ Kwan TT, Cheung AN, Lo SS et al. Psychological burden of testing positive for high-risk human papillomavirus on women with atypical cervical cytology: a prospective study. *Acta Obstetrica et Gynecologica Scandinavica*. 2011; 90(5): 445-51.
- ¹³⁹ Hendry M, Pasterfield D, Lewis R et al. Are women ready for the new cervical screening protocol in England? A systematic review and qualitative synthesis of views about human papillomavirus testing. *British Journal of Cancer* 2012; 107(2): 243-54.
- ¹⁴⁰ McCaffery KJ, Irwig L, Turner R et al. Psychosocial outcomes of three triage methods for the management of borderline abnormal cervical smears: an open randomised trial. *British Medical Journal*. 2010; 340: b4491.
- ¹⁴¹ Kitchener HC, Fletcher I, Roberts C et al. The psychosocial impact of human papillomavirus testing in primary cervical screening—a study within a randomized trial. *International Journal of Gynecological Cancer*. 2008; 18(4): 743-8.
- ¹⁴² Mayrand MH, Duarte-Franco E, Rodrigues I et al. Human papillomavirus DNA versus Papanicolaou screening tests for cervical cancer. *The New England Journal of Medicine*. 2007; 357(16): 1579-88.
- ¹⁴³ Berkhof J, Meijer CJ. Letter to the Editor. *The New England Journal of Medicine*. 2008; 358(6): 642.
- ¹⁴⁴ Naucler P, Ryd W, Tornberg S et al. Human papillomavirus and Papanicolaou tests to screen for cervical cancer. *The New England Journal of Medicine*. 2007; 357(16): 1589-97.
- ¹⁴⁵ Naucler P, Ryd W, Tornberg S et al. Efficacy of HPV DNA testing with cytology triage and/or repeat HPV DNA testing in primary cervical cancer screening. *Journal of the National Cancer Institute*. 2009; 101(2): 88-99.
- ¹⁴⁶ Ronco G, Segnan N, Giorgi-Rossi P et al. Human papillomavirus testing and liquid-based cytology: results at recruitment from the new technologies for cervical cancer randomized controlled trial. *Journal of the National Cancer Institute*. 2006; 98(11): 765-74.
- ¹⁴⁷ Ronco G, Giorgi-Rossi P, Carozzi F et al. Human papillomavirus testing and liquid-based cytology in primary screening of women younger than 35 years: results at recruitment for a randomised controlled trial. *The Lancet Oncology*. 2006; 7(7): 547-55.
- ¹⁴⁸ Ronco G, Giorgi-Rossi P, Carozzi F et al. Results at recruitment from a randomized controlled trial comparing human papillomavirus testing alone with conventional cytology as the primary cervical cancer screening test. *Journal of the National Cancer Institute*. 2008; 100(7): 492-501.
- ¹⁴⁹ Ronco G, Giorgi-Rossi P, Carozzi F et al. Efficacy of human papillomavirus testing for the detection of invasive cervical cancers and cervical intraepithelial neoplasia: a randomised controlled trial. *The Lancet Oncology*. 2010; 11(3): 249-57.
- ¹⁵⁰ Ronco G, Giorgi-Rossi P, Carozzi F et al. Efficacy of human papillomavirus testing for the detection of invasive cervical cancers and cervical intraepithelial neoplasia: a randomised controlled trial. *The Lancet Oncology*. 2010; 11(3): 249-57.

- ¹⁵¹ Bulkmand N, Berkhof J, Rozendaal L et al. Human papillomavirus DNA testing for the detection of cervical intraepithelial neoplasia grade 3 and cancer: 5-year follow-up of a randomised controlled implementation trial. *The Lancet*. 2007; 370(9601): 1764-72.
- ¹⁵² Rijkaart DC, Berkhof J, Rozendaal L et al. Human papillomavirus testing for the detection of high-grade cervical intraepithelial neoplasia and cancer: final results of the POBASCAM randomised controlled trial. *The Lancet Oncology*. 2012; 13: 78-88.
- ¹⁵³ Kitchener HC, Almonte M, Thomson C et al. HPV testing in combination with liquid-based cytology in primary cervical screening (ARTISTIC): a randomised controlled trial. *The Lancet Oncology*. 2009; 10(7): 672-82.
- ¹⁵⁴ Kitchener HC, Gilham C, Sargent A et al. A comparison of HPV DNA testing and liquid based cytology over three rounds of primary cervical screening: extended follow up in the ARTISTIC trial. *European Journal of Cancer*. 2011; 47(6): 864-71.
- ¹⁵⁵ Castle PE, Fetterman B, Poitras N et al. Five-year experience of human papillomavirus DNA and Papanicolaou test cotesting. *Obstetrics and Gynecology*. 2009; 113(3): 595-600.
- ¹⁵⁶ Kinney W, Fetterman B, Cox JT et al. Characteristics of 44 cervical cancers diagnosed following Pap-negative, high risk HPV-positive screening in routine clinical practice. *Gynecologic Oncology*. 2011; 121(2): 309-13.
- ¹⁵⁷ Katki HA, Kinney WK, Fetterman B et al. Cervical cancer risk for women undergoing concurrent testing for human papillomavirus and cervical cytology: a population-based study in routine clinical practice. *The Lancet Oncology*. 2011; 12(7): 663-72.
- ¹⁵⁸ Littell RD, Kinney W, Fetterman B et al. Risk of cervical precancer and cancer in women aged 30 years and older with an HPV-negative low-grade squamous intraepithelial lesion screening result. *Journal of Lower Genital Tract Disease*. 2011; 15(1): 54-9.
- ¹⁵⁹ Katki HA, Kinney WK, Fetterman B et al. Cervical cancer risk for women undergoing concurrent testing for human papillomavirus and cervical cytology: a population-based study in routine clinical practice. *The Lancet Oncology*. 2011; 12(7): 663-72.
- ¹⁶⁰ The denominator is based on a screening rate of 70% for the 1,151,500 women ages 30-64 in B.C. in 2015.
- ¹⁶¹ Katki HA, Kinney WK, Fetterman B et al. Cervical cancer risk for women undergoing concurrent testing for human papillomavirus and cervical cytology: a population-based study in routine clinical practice. *The Lancet Oncology*. 2011; 12(7): 663-72.
- ¹⁶² Ronco G, Dillner J, Elfström KM et al. Efficacy of HPV-based screening for prevention of invasive cervical cancer: follow-up of four European randomised controlled trials. *The Lancet*. 2014; 383(9916): 524-32.
- ¹⁶³ Isidean SD and Franco EL. Embracing a new era in cervical cancer screening. *The Lancet*. 2014; 383(9916): 493-4.
- ¹⁶⁴ Isidean SD and Franco EL. Embracing a new era in cervical cancer screening. *The Lancet*. 2014; 383(9916): 493-4.
- ¹⁶⁵ Dijkstra M, Snijders P, Arbyn M et al. Cervical cancer screening: on the way to a shift from cytology to full molecular screening. *Annals of Oncology*. 2014; 25: 927-35.
- ¹⁶⁶ Arbyn M, Roelens J, Simoens C et al. Human papillomavirus testing versus repeat cytology for triage of minor cytological cervical lesions. *Cochrane Database of Systematic Reviews*. 2013; 3.
- ¹⁶⁷ U.S. Food and Drug Administration. *Recently Approved Devices: cobas® HPV Test - P100020/S008*. 2014. Available at <http://www.fda.gov/MedicalDevices/ProductsandMedicalProcedures/DeviceApprovalsandClearances/Recently-ApprovedDevices/ucm395694.htm>. Accessed June 2015.

- ¹⁶⁸ Roche Canada. *Medial Release: Health Canada Approves Roche's HPV Test for First-Line Primary Screening of Cervical Cancer and Roche Launches New Cytology Test to Provide the Most Comprehensive Portfolio for Cervical Cancer Screening*. 2014. Available at http://www.rochecanada.com/en/content/news/health_canada_approves_roches_hpv_test.html. Accessed June 2015.
- ¹⁶⁹ Whitlock EP, Vesco KK, Eder M et al. Liquid-based cytology and human papillomavirus testing to screen for cervical cancer: a systematic review for the U.S. Preventive Services Task Force. *Annals of Internal Medicine*. 2011; 155(10): 687-97, W214-5.
- ¹⁷⁰ Vesco K, Whitlock E, Eder M et al. *Screening for Cervical Cancer: A Systematic Evidence Review for the U.S. Preventive Services Task Force*. 2011. Available at <http://www.ahrq.gov/downloads/pub/prevent/pdfser/cervcancer.pdf>. Accessed January 2012.
- ¹⁷¹ Jayasinghe YL, Moore EE, Tabrizi SN et al. Human papillomavirus in adolescents: lessons learned from decades of evaluation. *Journal of Paediatrics and Child Health*. 2013; 49(2): 99-104.
- ¹⁷² Personal communication with Dr. Andy Coldman, Vice President, Population Oncology, BC Cancer Agency, February 10, 2012. Chart based on data from the B.C. Cancer Registry.
- ¹⁷³ Katki HA, Kinney WK, Fetterman B et al. Cervical cancer risk for women undergoing concurrent testing for human papillomavirus and cervical cytology: a population-based study in routine clinical practice. *The Lancet Oncology*. 2011; 12(7): 663-72.
- ¹⁷⁴ Wilson J and Jungner G. *Principles and Practice of Screening for Disease*. 1968. World Health Organization. Available at http://whqlibdoc.who.int/php/WHO_PHP_34.pdf. Accessed January 2012.
- ¹⁷⁵ See *International Rare Cancer Initiative Newsletter*. Available at <http://newsletter.eortc.be/?p=1946>. Accessed March 2012.
- ¹⁷⁶ See ESMO Recommendations on Improving Rare Cancer Care in Europe. Available at http://www.esmo.org/fileadmin/media/pdf/policies/ESMO_Rare_Cancers_RECOMMENDATIONS.pdf. Accessed March 2012.
- ¹⁷⁷ Gustafsson L, Ponten J, Bergstrom R et al. International incidence rates of invasive cervical cancer before cytological screening. *International Journal of Cancer*. 1997; 71(2): 159-65.
- ¹⁷⁸ In this study, the age at onset was determined as follows: "the age at which the incidence rate starts to increase markedly (onset), defined as the age at which a straight line (fitted to the segment between 10 and 40% of the increase from zero to peak) intersects the age axis."
- ¹⁷⁹ Gustafsson L, Ponten J, Zack M et al. International incidence rates of invasive cervical cancer after introduction of cytological screening. *Cancer Causes & Control*. 1997; 8(5): 755-63.
- ¹⁸⁰ IARC, *Cancer Incidence in Five Continents Annual Dataset* available online at <http://ci5.iarc.fr/Ci5plus/ci5plus.htm>. Accessed January 2012.
- ¹⁸¹ van der Aa MA, Pukkala E, Coebergh JW et al. Mass screening programmes and trends in cervical cancer in Finland and the Netherlands. *International Journal of Cancer*. 2008; 122(8): 1854-8.
- ¹⁸² Popadiuk C, Stankiewicz A, Dickinson J et al. Invasive Cervical Cancer Incidence and Mortality Among Canadian Women Aged 15 to 29 and the Impact of Screening. *Journal of Obstetrics and Gynaecology Canada*. 2012; 34(12): 1167-76.
- ¹⁸³ Andrae B, Kemetli L, Sparen P et al. Screening-preventable cervical cancer risks: evidence from a nationwide audit in Sweden. *Journal of the National Cancer Institute*. 2008; 100(9): 622-9.
- ¹⁸⁴ Lönnberg S, Anttila A, Luostarinen T et al. Age-specific effectiveness of the Finnish cervical cancer screening programme. *Cancer Epidemiology Biomarkers & Prevention*. 2012; 21(8): 1354-61.
- ¹⁸⁵ Sasieni P, Castanon A and Cuzick J. Effectiveness of cervical screening with age: population based case-control study of prospectively recorded data. *British Medical Journal*. 2009; 339: b2968.
- ¹⁸⁶ Andrae B, Kemetli L, Sparen P et al. Screening-preventable cervical cancer risks: evidence from a nationwide audit in Sweden. *Journal of the National Cancer Institute*. 2008; 100(9): 622-9.

- ¹⁸⁷ Lönnberg S, Anttila A, Luostarinen T et al. Age-specific effectiveness of the Finnish cervical cancer screening programme. *Cancer Epidemiology Biomarkers & Prevention*. 2012; 21(8): 1354-61.
- ¹⁸⁸ Sasieni P, Castanon A and Cuzick J. What is the right age for cervical cancer screening? *Women's Health*. 2010; 6(1): 1-4.
- ¹⁸⁹ Sasieni P, Castanon A and Cuzick J. Effectiveness of cervical screening with age: population based case-control study of prospectively recorded data. *British Medical Journal*. 2009; 339: b2968.
- ¹⁹⁰ Sasieni P, Castanon A, Cuzick J. Effectiveness of cervical screening with age: population based case-control study of prospectively recorded data. *British Medical Journal*. 2009; 339: b2968.
- ¹⁹¹ Health Council of the Netherlands. *Population Screening for Cervical Cancer*. 2009. Available at http://www.gr.nl/sites/default/files/201107E%20PopulationSCC_0.pdf. Accessed March 2012.
- ¹⁹² Wise J. Age for starting cervical cancer screening in England will not be lowered. *British Medical Journal*. 2009; 338: b2583.
- ¹⁹³ Stapley S and Hamilton W. Gynaecological symptoms reported by young women: examining the potential for earlier diagnosis of cervical cancer. *Family Practice*. 2011; 28(6): 592-8.
- ¹⁹⁴ Foley G, Alston R, Geraci M et al. Increasing rates of cervical cancer in young women in England: an analysis of national data 1982–2006. *British Journal of Cancer*. 2011; 105(1): 177-84.
- ¹⁹⁵ Castanon A, Leung V, Landy R et al. Characteristics and screening history of women diagnosed with cervical cancer aged 20–29 years. *British Journal of Cancer*. 2013; 109(1): 35-41.
- ¹⁹⁶ Patel A, Galaal K, Burnley C et al. Cervical cancer incidence in young women: a historical and geographic controlled UK regional population study. *British Journal of Cancer*. 2012; 106(11): 1753-9.
- ¹⁹⁷ Sasieni P and Castanon A. Dramatic increase in cervical cancer registrations in young women in 2009 in England unlikely to be due to the new policy not to screen women aged 20–24. *Journal of Medical Screening*. 2012; 19(3): 127-32.
- ¹⁹⁸ Patel A, Galaal K, Burnley C et al. Cervical cancer incidence in young women: a historical and geographic controlled UK regional population study. *British Journal of Cancer*. 2012; 106(11): 1753-9.
- ¹⁹⁹ Castanon A, Leung V, Landy R et al. Characteristics and screening history of women diagnosed with cervical cancer aged 20–29 years. *British Journal of Cancer*. 2013; 109(1): 35-41.
- ²⁰⁰ Bruinsma FJ and Quinn MA. The risk of preterm birth following treatment for precancerous changes in the cervix: a systematic review and meta-analysis. *British Journal of Obstetrics and Gynaecology*. 2011; 118(9): 1031-41.
- ²⁰¹ Woodman CB, Collins SI and Young LS. The natural history of cervical HPV infection: unresolved issues. *Nature Reviews: Cancer*. 2007; 7(1): 11-22.
- ²⁰² Wright TC, Jr., Massad LS, Dunton CJ et al. 2006 consensus guidelines for the management of women with abnormal cervical screening tests. *Journal of Lower Genital Tract Disease*. 2007; 11(4): 201-22.
- ²⁰³ Krueger H, Kwon J, Sadownik L et al. What is the most appropriate age to start screening women for cervical cancer? *British Columbia Medical Journal*. 2013; 25(6): 29.
- ²⁰⁴ Miller NF and Todd OE. Conization of the cervix. *Surgical Gynecology and Obstetrics*. 1938; 67: 265-70.
- ²⁰⁵ Kristensen J, Langhoff-Roos J and Kristensen FB. Increased risk of preterm birth in women with cervical conization. *Obstetrics and Gynecology*. 1993; 81(6): 1005-8.
- ²⁰⁶ Weber T and Obel E. Pregnancy complications following conization of the uterine cervix(II). *Acta Obstetrica et Gynecologica Scandinavica*. 1979; 58: 347-51.
- ²⁰⁷ Kristensen J, Langhoff-Roos J, Wittrup M et al. Cervical conization and preterm delivery/low birth weight. A systematic review of the literature. *Acta Obstetrica et Gynecologica Scandinavica*. 1993; 72(8): 640-4.
- ²⁰⁸ Kyrgiou M, Koliopoulos G, Martin-Hirsch P et al. Obstetric outcomes after conservative treatment for intraepithelial or early invasive cervical lesions: systematic review and meta-analysis. *The Lancet*. 2006; 367(9509): 489-98.

- ²⁰⁹ Bruinsma FJ and Quinn MA. The risk of preterm birth following treatment for precancerous changes in the cervix: a systematic review and meta-analysis. *British Journal of Obstetrics and Gynaecology*. 2011; 118(9): 1031-41.
- ²¹⁰ Arbyn M, Kyrgiou M, Simoens C et al. Perinatal mortality and other severe adverse pregnancy outcomes associated with treatment of cervical intraepithelial neoplasia: meta-analysis. *British Medical Journal*. 2008; 337: a1284.
- ²¹¹ Bruinsma FJ and Quinn MA. The risk of preterm birth following treatment for precancerous changes in the cervix: a systematic review and meta-analysis. *British Journal of Obstetrics and Gynaecology*. 2011; 118(9): 1031-41.
- ²¹² Bruinsma FJ and Quinn MA. The risk of preterm birth following treatment for precancerous changes in the cervix: a systematic review and meta-analysis. *British Journal of Obstetrics and Gynaecology*. 2011; 118(9): 1031-41.
- ²¹³ Conner SN, Frey HA, Cahill AG et al. Loop electrosurgical excision procedure and risk of preterm birth: a systematic review and meta-analysis. *Obstetrics and Gynecology*. 2014; 123(4): 752.
- ²¹⁴ Kyrgiou M, Koliopoulos G, Martin-Hirsch P et al. Obstetric outcomes after conservative treatment for intraepithelial or early invasive cervical lesions: systematic review and meta-analysis. *The Lancet*. 2006; 367(9509): 489-98.
- ²¹⁵ Arbyn M, Kyrgiou M, Simoens C et al. Perinatal mortality and other severe adverse pregnancy outcomes associated with treatment of cervical intraepithelial neoplasia: meta-analysis. *British Medical Journal*. 2008; 337: a1284.
- ²¹⁶ Noehr B, Jensen A, Frederiksen K et al. Depth of cervical cone removed by loop electrosurgical excision procedure and subsequent risk of spontaneous preterm delivery. *Obstetrics & Gynecology*. 2009; 114(6): 1232-8.
- ²¹⁷ Khalid S, Dimitriou E, Conroy R et al. The thickness and volume of LLETZ specimens can predict the relative risk of pregnancy-related morbidity. *BJOG: An International Journal of Obstetrics & Gynaecology*. 2012; 119(6): 685-91.
- ²¹⁸ Castanon A, Landy R, Brocklehurst P et al. Risk of preterm delivery with increasing depth of excision for cervical intraepithelial neoplasia in England: nested case-control study. *The BMJ*. 2014; 349: g6223.
- ²¹⁹ Kyrgiou M, Arbyn M, Martin-Hirsch P et al. Increased risk of preterm birth after treatment for CIN. *BMJ*. 2012; 345: e5847.
- ²²⁰ Castañón A, Landy R, Brocklehurst P et al. Is the increased risk of preterm birth following excision for cervical intraepithelial neoplasia restricted to the first birth post treatment? *BJOG: An International Journal of Obstetrics and Gynaecology*. 2015: E-published ahead of print.
- ²²¹ Bruinsma FJ and Quinn MA. The risk of preterm birth following treatment for precancerous changes in the cervix: a systematic review and meta-analysis. *British Journal of Obstetrics and Gynaecology*. 2011; 118(9): 1031-41.
- ²²² Martyn F, McAuliffe F and Wingfield M. The role of the cervix in fertility: is it time for a reappraisal? *Human Reproduction*. 2014; 29(10): 2092-8.
- ²²³ Martyn FM, McAuliffe FM, Beggan C et al. Excisional treatments of the cervix and effect on subsequent fertility: a retrospective cohort study. *European Journal of Obstetrics & Gynecology and Reproductive Biology*. 2015; 185: 114-20.
- ²²⁴ Kyrgiou M, Mitra A, Arbyn M et al. Fertility and early pregnancy outcomes after treatment for cervical intraepithelial neoplasia: systematic review and meta-analysis. *The BMJ*. 2014; 349: g6192.
- ²²⁵ Dong Y and Yu JL. An overview of morbidity, mortality and long-term outcome of late preterm birth. *World Journal of Pediatrics*. 2011; 7(3): 199-204.
- ²²⁶ Morse SB, Zheng H, Tang Y et al. Early school-age outcomes of late preterm infants. *Pediatrics*. 2009; 123(4): e622-9.

- ²²⁷ Petrini JR, Dias T, McCormick MC et al. Increased risk of adverse neurological development for late preterm infants. *The Journal of Pediatrics*. 2009; 154(2): 169-76.
- ²²⁸ Bird TM, Bronstein JM, Hall RW et al. Late preterm infants: birth outcomes and health care utilization in the first year. *Pediatrics*. 2010; 126(2): e311-9.
- ²²⁹ Gurka MJ, LoCasale-Crouch J and Blackman JA. Long-term cognition, achievement, socioemotional, and behavioral development of healthy late-preterm infants. *Archives of Pediatrics & Adolescent Medicine*. 2010; 164(6): 525-32.
- ²³⁰ Dong Y and Yu JL. An overview of morbidity, mortality and long-term outcome of late preterm birth. *World Journal of Pediatrics*. 2011; 7(3): 199-204.
- ²³¹ McGowan JE, Alderdice FA, Holmes VA et al. Early childhood development of late-preterm infants: a systematic review. *Pediatrics*. 2011; 127(6): 1111-24.
- ²³² Samra HA, McGrath JM and Wehbe M. An integrated review of developmental outcomes and late-preterm birth. *Journal of Obstetric, Gynecologic, and Neonatal Nursing*. 2011; 40(4): 399-411.
- ²³³ Ibid.
- ²³⁴ Bérard A, Le Tiec M and De Vera MA. Study of the costs and morbidities of late-preterm birth. *Archives of Disease in Childhood*. 2012; 97(5): F329-F34.
- ²³⁵ Kulasingam S, Havrilesky L, Ghebre R et al. *Screening for Cervical Cancer: A Decision Analysis for the U.S. Preventive Services Task Force*. 2011. Available at <http://www.uspreventiveservicestaskforce.org/uspstf11/cervcancer/cervcanceres.pdf>. Accessed January 2012.
- ²³⁶ Landy R, Birke H, Castanon A et al. Benefits and harms of cervical screening from age 20 years compared with screening from age 25 years. *British Journal of Cancer*. 2014; 110(7): 1841-6.
- ²³⁷ Canadian Task Force on Preventive Health Care. Recommendations on screening for cervical cancer. *Canadian Medical Association Journal*. 2013; 185(1): 35-45.
- ²³⁸ The Society of Obstetricians and Gynaecologists of Canada, The Society of Gynecologic Oncology of Canada and Society of Canadian Colposcopists. *Position Statement: Recommendations on Screening for Cervical Cancer*. 2013. Available at http://sogc.org/media_updates/the-sogc-the-scc-and-goc-issue-a-joint-position-statement-in-response-to-new-ctfphc-recommendations-on-screening-for-cervical-cancer/. Accessed July 2015.
- ²³⁹ Mandelblatt J, Lawrence W, Yi B et al. The balance of harms, benefits, and costs of screening for cervical cancer in older women: the case for continued screening. *Archives of Internal Medicine*. 2004; 164(3): 245-7; discussion 7-8.
- ²⁴⁰ Bernstein R, DeJoseph D and Buchanan EM. When to stop screening: a review of breast, gynecologic, and colorectal cancer screening in women over age 65. *Care Management Journals*. 2010; 11(1): 48-57.
- ²⁴¹ Ibid.
- ²⁴² Strander B. At what age should cervical screening stop? *British Medical Journal*. 2009; 338: b809.
- ²⁴³ Cancer Research UK statistics, 2005. Available at info.cancerresearchuk.org/cancerstats/types/cervix/.
- ²⁴⁴ Woodman CB, Collins SI and Young LS. The natural history of cervical HPV infection: unresolved issues. *Nature Reviews: Cancer*. 2007; 7(1): 11-22.
- ²⁴⁵ Smith EM, Johnson SR, Ritchie JM et al. Persistent HPV infection in postmenopausal age women. *International Journal of Gynecology & Obstetrics*. 2004; 87(2): 131-7.
- ²⁴⁶ Grainge MJ, Seth R, Guo L et al. Cervical human papillomavirus screening among older women. *Emerging Infectious Diseases*. 2005; 11(11): 1680-5.
- ²⁴⁷ Mandelblatt J, Lawrence W, Yi B et al. The balance of harms, benefits, and costs of screening for cervical cancer in older women: the case for continued screening. *Archives of Internal Medicine*. 2004; 164(3): 245-7; discussion 7-8.
- ²⁴⁸ Ibid.

- ²⁴⁹ Krueger H, Stuart G, Gallagher R et al. *HPV and Other Infectious Agents in Cancer: Opportunities for Prevention and Public Health*. New York: Oxford University Press; 2010.
- ²⁵⁰ Strander B. At what age should cervical screening stop? *British Medical Journal*. 2009; 338: b809.
- ²⁵¹ Rebolj M, van Ballegooijen M, Lynge E et al. Incidence of cervical cancer after several negative smear results by age 50: prospective observational study. *British Medical Journal*. 2009; 338: b1354.
- ²⁵² Mandelblatt J, Lawrence W, Yi B et al. The balance of harms, benefits, and costs of screening for cervical cancer in older women: the case for continued screening. *Archives of Internal Medicine*. 2004; 164(3): 245-7; discussion 7-8.
- ²⁵³ Blanks RG, Moss SM, Addou S et al. Risk of cervical abnormality after age 50 in women with previously negative smears. *British Journal of Cancer*. 2009; 100(11): 1832-6.
- ²⁵⁴ Rebolj M, van Ballegooijen M, Lynge E et al. Incidence of cervical cancer after several negative smear results by age 50: prospective observational study. *British Medical Journal*. 2009; 338: b1354.
- ²⁵⁵ Van Wijngaarden WJ and Duncan ID. Rationale for stopping cervical screening in women over 50. *British Medical Journal*. 1993; 306(6883): 967-71.
- ²⁵⁶ Cruickshank ME, Angus V, Kelly M et al. The case for stopping cervical screening at age 50. *British Journal of Obstetrics and Gynaecology*. 1997; 104(5): 586-9.
- ²⁵⁷ Andrae B, Kemetli L, Sparén P et al. Screening-preventable cervical cancer risks: evidence from a nationwide audit in Sweden. *Journal of the National Cancer Institute*. 2008; 100(9): 622-9.
- ²⁵⁸ Sasieni P, Castanon A and Cuzick J. Effectiveness of cervical screening with age: population based case-control study of prospectively recorded data. *BMJ*. 2009; 339:
- ²⁵⁹ Lönnberg S, Anttila A, Luostarinen T et al. Age-specific effectiveness of the Finnish cervical cancer screening programme. *Cancer Epidemiology Biomarkers & Prevention*. 2012; 21(8): 1354-61.
- ²⁶⁰ Kaminen A, Weinmann S, Shy KK et al. Efficacy of screening in preventing cervical cancer among older women. *Cancer Causes & Control*. 2013; 24(9): 1653-60.
- ²⁶¹ Flannelly G, Monaghan J, Cruickshank M et al. Cervical screening in women over the age of 50: results of a population-based multicentre study. *British Journal of Obstetrics and Gynaecology*. 2004; 111(4): 362-8.
- ²⁶² Blanks RG, Moss SM, Addou S et al. Risk of cervical abnormality after age 50 in women with previously negative smears. *British Journal of Cancer*. 2009; 100(11): 1832-6.
- ²⁶³ Rebolj M, van Ballegooijen M, Lynge E et al. Incidence of cervical cancer after several negative smear results by age 50: prospective observational study. *British Medical Journal*. 2009; 338: b1354.
- ²⁶⁴ Ibid
- ²⁶⁵ Castanon A, Landy R, Cuzick J et al. Cervical screening at age 50–64 years and the risk of cervical cancer at age 65 years and older: population-based case control study. *Public Library of Science Medicine*. 2014; 11(1): e1001585.
- ²⁶⁶ Rustagi AS, Kaminen A, Weinmann S et al. Cervical screening and cervical cancer death among older women: a population-based, case-control study. *American Journal of Epidemiology*. 2014; 179(9): 1107-17.
- ²⁶⁷ Mandelblatt J, Lawrence W, Yi B et al. The balance of harms, benefits, and costs of screening for cervical cancer in older women: the case for continued screening. *Archives of Internal Medicine*. 2004; 164(3): 245-7; discussion 7-8.
- ²⁶⁸ Canadian Task Force on Preventive Health Care. Recommendations on screening for cervical cancer. *Canadian Medical Association Journal*. 2013; 185(1): 35-45.
- ²⁶⁹ Strander B, Andersson-Ellstrom A, Milsom I et al. Long term risk of invasive cancer after treatment for cervical intraepithelial neoplasia grade 3: population based cohort study. *British Medical Journal*. 2007; 335(7629): 1077.
- ²⁷⁰ Ibid.

- ²⁷¹ Kalliala I, Anttila A, Pukkala E et al. Risk of cervical and other cancers after treatment of cervical intraepithelial neoplasia: retrospective cohort study. *British Medical Journal*. 2005; 331(7526): 1183-5.
- ²⁷² Einstein MH. Women whose cervical intraepithelial neoplasia has been treated or resolved remain at continued high risk for cervical cancer. *Evidence Based Medicine*. 2013; 18(5): 190-1.
- ²⁷³ Rebolj M, Helmerhorst T, Habbema D et al. Risk of cervical cancer after completed post-treatment follow-up of cervical intraepithelial neoplasia: population based cohort study. *BMJ*. 2012; 345: e6855.
- ²⁷⁴ Strander B, Hällgren J and Sparén P. Effect of ageing on cervical or vaginal cancer in Swedish women previously treated for cervical intraepithelial neoplasia grade 3: population based cohort study of long term incidence and mortality. *The BMJ*. 2014; 348: f7361.
- ²⁷⁵ Isidean SD and Franco EL. Counterpoint: cervical cancer screening guidelines—approaching the golden age. *American Journal of Epidemiology*. 2013; 178(7): 1023-6.
- ²⁷⁶ Sawaya GF, Grady D, Kerlikowske K et al. The positive predictive value of cervical smears in previously screened postmenopausal women: the Heart and Estrogen/progestin Replacement Study (HERS). *Annals of Internal Medicine*. 2000; 133(12): 942-50.
- ²⁷⁷ Sawaya GF. Should routine screening Papanicolaou smears be done for women older than 65 years? *Archives of Internal Medicine*. 2004; 164(3): 243-5.
- ²⁷⁸ Kulasingam SL, Havrilesky L, Ghebre R et al. *Screening for cervical cancer: a decision analysis for the US Preventive Services Task Force*. 2011. Agency for Healthcare Research and Quality. Available at http://www.ncbi.nlm.nih.gov.ezproxy.library.ubc.ca/books/NBK92546/pdf/Bookshelf_NBK92546.pdf. Accessed June 2015.
- ²⁷⁹ Saslow D, Solomon D, Lawson HW et al. American Cancer Society, American Society for Colposcopy and Cervical Pathology, and American Society for Clinical Pathology screening guidelines for the prevention and early detection of cervical cancer. *CA: A Cancer Journal for Clinicians*. 2012; 62(3): 147-72.
- ²⁸⁰ Stokes-Lampard H, Wilson S, Waddell C et al. Vaginal vault smears after hysterectomy for reasons other than malignancy: a systematic review of the literature. *British Journal of Obstetrics and Gynaecology*. 2006; 113(12): 1354-65.
- ²⁸¹ Canadian Institute for Health Information. *Health Indicators*. 2011. Available at http://secure.cihi.ca/cihiweb/products/health_indicators_2011_en.pdf. Accessed March 2012.
- ²⁸² Stokes-Lampard H, Wilson S, Waddell C et al. Vaginal vault smears after hysterectomy for reasons other than malignancy: a systematic review of the literature. *British Journal of Obstetrics and Gynaecology*. 2006; 113(12): 1354-65.
- ²⁸³ Strander B, Andersson-Ellstrom A, Milsom I et al. Long term risk of invasive cancer after treatment for cervical intraepithelial neoplasia grade 3: population based cohort study. *British Medical Journal*. 2007; 335(7629): 1077.
- ²⁸⁴ Arbyn M, Paraskevidis E, Martin-Hirsch P et al. Clinical utility of HPV-DNA detection: triage of minor cervical lesions, follow-up of women treated for high-grade CIN: an update of pooled evidence. *Gynecologic Oncology*. 2005; 99(3 Suppl 1): S7-11.
- ²⁸⁵ Arbyn M, Ronco G, Anttila A et al. Evidence regarding human papillomavirus testing in secondary prevention of cervical cancer. *Vaccine*. 2012; 30: F88-F99.
- ²⁸⁶ Verguts J, Bronselaer B, Donders G et al. Prediction of recurrence after treatment for high-grade cervical intraepithelial neoplasia: the role of human papillomavirus testing and age at conisation. *British Journal of Obstetrics and Gynaecology*. 2006; 113(11): 1303-7.
- ²⁸⁷ IARC Working Group on Evaluation of Cervical Cancer Screening Programmes. Screening for squamous cervical cancer: duration of low risk after negative results of cervical cytology and its implication for screening policies. *British Medical Journal*. 1986; 293(6548): 659-64.
- ²⁸⁸ Sasieni P and Castanon A. Call and recall cervical screening programme: Screening interval and age limits. *Current Diagnostic Pathology*. 2006; 12: 114-26.

- ²⁸⁹ Sawaya GF, McConnell KJ, Kulasingam SL et al. Risk of cervical cancer associated with extending the interval between cervical-cancer screenings. *The New England Journal of Medicine*. 2003; 349(16): 1501-9.
- ²⁹⁰ Sasieni P and Castanon A. Call and recall cervical screening programme: Screening interval and age limits. *Current Diagnostic Pathology*. 2006; 12: 114-26.
- ²⁹¹ Sirovich BE and Welch HG. The frequency of Pap smear screening in the United States. *Journal of General Internal Medicine*. 2004; 19(3): 243-50.
- ²⁹² Sawaya GF, Kerlikowske K, Lee NC et al. Frequency of cervical smear abnormalities within 3 years of normal cytology. *Obstetrics and Gynecology*. 2000; 96(2): 219-23.
- ²⁹³ Canfell K, Sitas F and Beral V. Cervical cancer in Australia and the United Kingdom: comparison of screening policy and uptake, and cancer incidence and mortality. *The Medical Journal of Australia*. 2006; 185(9): 482-6.
- ²⁹⁴ Bulkmans N, Berkhof J, Rozendaal L et al. Human papillomavirus DNA testing for the detection of cervical intraepithelial neoplasia grade 3 and cancer: 5-year follow-up of a randomised controlled implementation trial. *The Lancet*. 2007; 370(9601): 1764-72.
- ²⁹⁵ Kitchener HC, Gilham C, Sargent A et al. A comparison of HPV DNA testing and liquid based cytology over three rounds of primary cervical screening: extended follow up in the ARTISTIC trial. *European Journal of Cancer*. 2011; 47(6): 864-71.
- ²⁹⁶ Rijkaart DC, Berkhof J, Rozendaal L et al. Human papillomavirus testing for the detection of high-grade cervical intraepithelial neoplasia and cancer: final results of the POBASCAM randomised controlled trial. *The Lancet Oncology*. 2012; 13: 78-88.
- ²⁹⁷ Cuzick J, Arbyn M, Sankaranarayanan R et al. Overview of human papillomavirus-based and other novel option for cervical cancer screening in developed and developing countries. *Vaccine*. 2008; 26S: K29-K41.
- ²⁹⁸ Castle PE, Stoler MH, Wright TC, Jr. et al. Performance of carcinogenic human papillomavirus (HPV) testing and HPV16 or HPV18 genotyping for cervical cancer screening of women aged 25 years and older: a subanalysis of the ATHENA study. *The Lancet Oncology*. 2011; 12(9): 880-90.
- ²⁹⁹ Rijkaart DC, Berkhof J, van Kemenade FJ et al. Evaluation of 14 triage strategies for HPV DNA-positive women in population-based cervical screening. *International Journal of Cancer*. 2012; 130(3): 602-10.
- ³⁰⁰ Rijkaart D, Berkhof J, van Kemenade F et al. HPV DNA testing in population-based cervical screening (VUSA-Screen study): results and implications. *British Journal of Cancer*. 2012; 106(5): 975-81.
- ³⁰¹ Wright TC, Jr., Massad LS, Dunton CJ et al. 2006 consensus guidelines for the management of women with abnormal cervical cancer screening tests. *American Journal of Obstetrics and Gynecology*. 2007; 197(4): 346-55.
- ³⁰² Kitchener HC, Almonte M, Thomson C et al. HPV testing in combination with liquid-based cytology in primary cervical screening (ARTISTIC): a randomised controlled trial. *The Lancet Oncology*. 2009; 10(7): 672-82.
- ³⁰³ Kinney W, Fetterman B, Cox JT et al. Characteristics of 44 cervical cancers diagnosed following Pap-negative, high risk HPV-positive screening in routine clinical practice. *Gynecologic Oncology*. 2011; 121(2): 309-13.
- ³⁰⁴ Castle PE, Stoler MH, Wright TC, Jr. et al. Performance of carcinogenic human papillomavirus (HPV) testing and HPV16 or HPV18 genotyping for cervical cancer screening of women aged 25 years and older: a subanalysis of the ATHENA study. *The Lancet Oncology*. 2011; 12(9): 880-90.
- ³⁰⁵ Khan MJ, Castle PE, Lorincz AT et al. The elevated 10-year risk of cervical precancer and cancer in women with human papillomavirus (HPV) type 16 or 18 and the possible utility of type-specific HPV testing in clinical practice. *Journal of the National Cancer Institute*. 2005; 97(14): 1072-9.
- ³⁰⁶ Rijkaart DC, Berkhof J, van Kemenade FJ et al. Evaluation of 14 triage strategies for HPV DNA-positive women in population-based cervical screening. *International Journal of Cancer*. 2012; 130(3): 602-10.

- ³⁰⁷ In the 2001 Bethesda system, BMD corresponds to atypical squamous cells of undetermined significance, atypical squamous cells, cannot exclude high-grade squamous intraepithelial lesions, or low-grade squamous intraepithelial lesions.
- ³⁰⁸ In the 2001 Bethesda system, >BMD corresponds to high-grade squamous or glandular intraepithelial lesions.
- ³⁰⁹ Rijkaart D, Berkhof J, van Kemenade F et al. HPV DNA testing in population-based cervical screening (VUSA-Screen study): results and implications. *British Journal of Cancer*. 2012; 106(5): 975-81.
- ³¹⁰ Rijkaart DC, Berkhof J, van Kemenade FJ et al. Evaluation of 14 triage strategies for HPV DNA-positive women in population-based cervical screening. *International Journal of Cancer*. 2012; 130(3): 602-10.
- ³¹¹ Dijkstra MG, van Niekerk D, Rijkaart DC et al. Primary hrHPV DNA testing in cervical cancer screening: how to manage screen-positive women? A POBASCAM trial substudy. *Cancer Epidemiology Biomarkers & Prevention*. 2014; 23(1): 55-63.
- ³¹² Ogilvie G, Krajden M, Van Niekerk D et al. Primary cervical cancer screening with HPV testing compared with liquid-based cytology: results of round 1 of a randomised controlled trial—the HPV FOCAL Study. *British Journal of Cancer*. 2012; 107(12): 1917-24.
- ³¹³ Almonte M, Sasieni P and Cuzick J. Incorporating human papillomavirus testing into cytological screening in the era of prophylactic vaccines. *Best Practice & Research. Clinical Obstetrics & Gynaecology*. 2011; 25(5): 617-29.
- ³¹⁴ Ronco G, Giorgi-Rossi P, Carozzi F et al. Human papillomavirus testing and liquid-based cytology in primary screening of women younger than 35 years: results at recruitment for a randomised controlled trial. *The Lancet Oncology*. 2006; 7(7): 547-55.
- ³¹⁵ Del Mistro A, Frayle H, Ferro A et al. Cervical cancer screening by high risk HPV testing in routine practice: results at one year recall of high risk HPV-positive and cytology-negative women. *Journal of Medical Screening*. 2014; 21(1): 30-7.
- ³¹⁶ Leinonen M, Nieminen P, Kotaniemi-Talonen L et al. Age-specific evaluation of primary human papillomavirus screening vs conventional cytology in a randomized setting. *Journal of the National Cancer Institute*. 2009; 101(23): 1612-23.
- ³¹⁷ Cuzick J, Arbyn M, Sankaranarayanan R et al. Overview of human papillomavirus-based and other novel options for cervical cancer screening in developed and developing countries. *Vaccine*. 2008; 26 Suppl 10: K29-41.
- ³¹⁸ Schiffman M, Castle PE, Jeronimo J et al. Human papillomavirus and cervical cancer. *The Lancet*. 2007; 370(9590): 890-907.
- ³¹⁹ Kitchener HC, Gilham C, Sargent A et al. A comparison of HPV DNA testing and liquid based cytology over three rounds of primary cervical screening: extended follow up in the ARTISTIC trial. *European Journal of Cancer*. 2011; 47(6): 864-71.
- ³²⁰ On April 1, 2015 Merck's new HPV vaccine, Gardasil 9, was approved for use in Canada. Gardasil 9 targets HPV types 16, 18, 6, 11, 31, 33, 45, 52 and 58. Merck Canada Inc. *News Release: Merck's HPV Vaccine, GARDASIL 9, Now Available in Canada*. 2015. Available at <http://www.merck.ca/Assets/News/FINAL%20Press%20Release%20GARDASIL9%20-%20EN.pdf>. Accessed June 2015.
- ³²¹ Krueger H, Stuart G, Gallagher R et al. *HPV and Other Infectious Agents in Cancer: Opportunities for Prevention and Public Health*. New York: Oxford University Press; 2010.
- ³²² Ronco G, Dillner J, Elfström KM et al. Efficacy of HPV-based screening for prevention of invasive cervical cancer: follow-up of four European randomised controlled trials. *The Lancet*. 2014; 383(9916): 524-32.
- ³²³ Bernstein R, DeJoseph D and Buchanan EM. When to stop screening: a review of breast, gynecologic, and colorectal cancer screening in women over age 65. *Care Management Journals*. 2010; 11(1): 48-57.

- ³²⁴ Saslow D, Solomon D, Lawson HW et al. American Cancer Society, American Society for Colposcopy and Cervical Pathology, and American Society for Clinical Pathology screening guidelines for the prevention and early detection of cervical cancer. *CA: A Cancer Journal for Clinicians*. 2012; 62(3): 147-72.
- ³²⁵ Canadian Task Force on Preventive Health Care. Recommendations on screening for cervical cancer. *Canadian Medical Association Journal*. 2013; 185(1): 35-45.
- ³²⁶ Castle PE, Stoler MH, Wright TC, Jr. et al. Performance of carcinogenic human papillomavirus (HPV) testing and HPV16 or HPV18 genotyping for cervical cancer screening of women aged 25 years and older: a subanalysis of the ATHENA study. *The Lancet Oncology*. 2011; 12(9): 880-90.
- ³²⁷ Rijkaart DC, Berkhof J, van Kemenade FJ et al. Evaluation of 14 triage strategies for HPV DNA-positive women in population-based cervical screening. *International Journal of Cancer*. 2012; 130(3): 602-10.
- ³²⁸ Herrero R, González P and Markowitz LE. Present status of human papillomavirus vaccine development and implementation. *The Lancet Oncology*. 2015; 16(5): e206-16.
- ³²⁹ Herrero R, González P and Markowitz LE. Present status of human papillomavirus vaccine development and implementation. *The Lancet Oncology*. 2015; 16(5): e206-16.
- ³³⁰ Tabrizi SN, Brotherton JM, Kaldor JM et al. Fall in human papillomavirus prevalence following a national vaccination program. *Journal of Infectious Diseases*. 2012; 206(11): 1645-51.
- ³³¹ Pollock KG, Kavanagh K, Potts A et al. Reduction of low-and high-grade cervical abnormalities associated with high uptake of the HPV bivalent vaccine in Scotland. *British Journal of Cancer*. 2014; 111(9): 1824-30.
- ³³² Ogilvie GS, Naus M, Money DM et al. Reduction in cervical intraepithelial neoplasia in young women in British Columbia after introduction of the HPV vaccine: An ecological analysis. *International Journal of Cancer*. 2015: E-published ahead of print.
- ³³³ Drolet M, Bénard É, Boily M-C et al. Population-level impact and herd effects following human papillomavirus vaccination programmes: a systematic review and meta-analysis. *The Lancet Infectious Diseases*. 2015; 15(5): 565-80.
- ³³⁴ Merck Canada Inc. *News Release: Merck's HPV Vaccine, GARDASIL 9, Now Available in Canada*. 2015. Available at <http://www.merck.ca/Assets/News/FINAL%20Press%20Release%20GARDASIL9%20-%20EN.pdf>. Accessed June 2015.
- ³³⁵ Joura EA, Giuliano AR, Iversen O-E et al. A 9-valent HPV vaccine against infection and intraepithelial neoplasia in women. *New England Journal of Medicine*. 2015; 372(8): 711-23.
- ³³⁶ Schiller JT and Müller M. Next generation prophylactic human papillomavirus vaccines. *The Lancet Oncology*. 2015; 16(5): e217-25.
- ³³⁷ Schiffman M and Solomon D. Screening and prevention methods for cervical cancer. *Journal of the American Medical Association*. 2009; 302(16): 1809-10.
- ³³⁸ Cuzick J, Clavel C, Petry KU et al. Overview of the European and North American studies on HPV testing in primary cervical cancer screening. *International Journal of Cancer*. 2006; 119(5): 1095-101.
- ³³⁹ Dillner L, Kemetli L, Elfgrén K et al. Randomized healthservices study of human papillomavirus-based management of low-grade cytological abnormalities. *International Journal of Cancer*. 2011; 129(1): 151-9.
- ³⁴⁰ Van Rosmalen J, de Kok I and Van Ballegooijen M. Cost-effectiveness of cervical cancer screening: cytology versus human papillomavirus DNA testing. *BJOG: An International Journal of Obstetrics & Gynaecology*. 2012; 119(6): 699-709.
- ³⁴¹ Schiffman M, Castle PE, Jeronimo J et al. Human papillomavirus and cervical cancer. *The Lancet*. 2007; 370(9590): 890-907.
- ³⁴² Public Health Agency of Canada. *Performance Monitoring for Cervical Cancer Screening Programs in Canada*. 2009. Available at <http://www.phac-aspc.gc.ca/cd-mc/cancer/pmccspc-srpdccuc/pdf/cervical-eng.pdf>. Accessed January 2012.

- ³⁴³ Health Council of the Netherlands. *Population Screening for Cervical Cancer*. 2009. Available at http://www.gr.nl/sites/default/files/201107E%20PopulationSCC_0.pdf. Accessed March 2012.
- ³⁴⁴ Mitchell S, Ogilvie G, Steinberg M et al. Assessing women's willingness to collect their own cervical samples for HPV testing as part of the ASPIRE cervical cancer screening project in Uganda. *International Journal of Gynaecology and Obstetrics*. 2011; 114(2): 111-5.
- ³⁴⁵ Gok M, Heideman DA, van Kemenade FJ et al. HPV testing on self collected cervicovaginal lavage specimens as screening method for women who do not attend cervical screening: cohort study. *British Medical Journal*. 2010; 340: c1040.
- ³⁴⁶ Sowjanya AP, Paul P, Vedantham H et al. Suitability of self-collected vaginal samples for cervical cancer screening in periurban villages in Andhra Pradesh, India. *Cancer Epidemiology, Biomarkers & Prevention*. 2009; 18(5): 1373-8.
- ³⁴⁷ Arbyn M, Verdoodt F, Snijders PJ et al. Accuracy of human papillomavirus testing on self-collected versus clinician-collected samples: a meta-analysis. *The Lancet Oncology*. 2014; 15(2): 172-83.
- ³⁴⁸ Snijders PJ, Verhoef VM, Arbyn M et al. High-risk HPV testing on self-sampled versus clinician-collected specimens: a review on the clinical accuracy and impact on population attendance in cervical cancer screening. *International Journal of Cancer*. 2013; 132(10): 2223-36.
- ³⁴⁹ Wright TC, Jr., Denny L, Kuhn L et al. HPV DNA testing of self-collected vaginal samples compared with cytologic screening to detect cervical cancer. *Journal of the American Medical Association*. 2000; 283(1): 81-6.
- ³⁵⁰ Black AT, McCulloch A, Martin RE et al. Young women and cervical cancer screening: what barriers persist? *The Canadian Journal of Nursing Research*. 2011; 43(1): 8-21.
- ³⁵¹ Abdullahi A, Copping J, Kessel A et al. Cervical screening: Perceptions and barriers to uptake among Somali women in Camden. *Public Health*. 2009; 123(10): 680-5.
- ³⁵² Racey CS, Withrow DR and Gesink D. Self-collected HPV testing improves participation in cervical cancer screening: a systematic review and meta-analysis. *Canadian Journal of Public Health*. 2013; 104(2): e159-e66.
- ³⁵³ Castle PE, Rausa A, Walls T et al. Comparative community outreach to increase cervical cancer screening in the Mississippi Delta. *Preventive Medicine*. 2011; 52(6): 452-5.
- ³⁵⁴ Heideman DA, Snijders PJ, Berkhof J et al. Vaccination against HPV: indications for women and the impact on the cervical screening programme. *British Journal of Obstetrics and Gynaecology*. 2008; 115(8): 938-46.
- ³⁵⁵ Hermens RP, Hak E, Hulscher ME et al. Adherence to guidelines on cervical cancer screening in general practice: programme elements of successful implementation. *The British Journal of General Practice*. 2001; 51(472): 897-903.
- ³⁵⁶ Wai D, Ferrier A, Collings S et al. Have the most recent Pap smear guidelines affected GP practices? *Australian Family Physician*. 1996; Suppl 1: S44-8.
- ³⁵⁷ Holland-Barkis P, Forjuoh SN, Couchman GR et al. Primary care physicians' awareness and adherence to cervical cancer screening guidelines in Texas. *Preventive Medicine*. 2006; 42(2): 140-5.
- ³⁵⁸ Yabroff KR, Saraiya M, Meissner HI et al. Specialty differences in primary care physician reports of papanicolaou test screening practices: a national survey, 2006 to 2007. *Annals of Internal Medicine*. 2009; 151(9): 602-11.
- ³⁵⁹ Hermens RP, Hak E, Hulscher ME et al. Adherence to guidelines on cervical cancer screening in general practice: programme elements of successful implementation. *The British Journal of General Practice*. 2001; 51(472): 897-903.

³⁶⁰ Bluman B, Kan L, Lynn B et al. *Primary Care Physician Education and Engagement in the Promotion of Recommended Cancer Screening in BC: Report on a Province-wide Cancer Screening Needs Assessment*. 2010. Available at <http://www.bccancer.bc.ca/NR/rdonlyres/3441FFE3-562E-4970-BACD-7EB1AF3B8309/48309/BCCancerScreeningNeedsAssessmentExecutiveSummary.pdf>. Accessed January 2012.

³⁶¹ Fylan F. Screening for cervical cancer: a review of women's attitudes, knowledge, and behaviour. *The British Journal of General Practice*. 1998; 48(433): 1509-14.

³⁶² Ibid

³⁶³ Bluman B, Kan L, Lynn B et al. *Primary Care Physician Education and Engagement in the Promotion of Recommended Cancer Screening in BC: Report on a Province-wide Cancer Screening Needs Assessment*. 2010. Available at <http://www.bccancer.bc.ca/NR/rdonlyres/3441FFE3-562E-4970-BACD-7EB1AF3B8309/48309/BCCancerScreeningNeedsAssessmentExecutiveSummary.pdf>. Accessed January 2012.